Progress report on phase I/II clinical trial of Ad-OC-TK plus VAL therapy for metastatic or locally recurrent prostate cancer: Initial experience at Kobe University.

Abstract

There is no effective therapy for hormone-refractory prostate cancer and a novel therapeutic modality, such as a gene therapy, should be actively pursued. Previously, Gardner and Chung conducted a phase I clinical trial of Ad-OC-TK (recombinant adenoviral vector containing osteocalcin promoter-driven herpes simplex virus thymidine kinase gene) plus VAL (valacyclovir) for the treatment of hormone-refractory prostate cancer at the University of Virginia. We report on our ongoing phase I/II clinical trial of Ad-OC-TK plus VAL for the treatment of advanced prostate cancer at the Kobe University Hospital, Japan.

• Authors: Nobuyuki Hinata, Toshiro Shirakawa, Shuji Terao, Kazumasa Goda, Kazushi Tanaka, Yuji Yamada, Isao Hara, Sadao Kamidono, Masato Fujisawa, Akinobu Gotoh
• Journal: International journal of urology : official journal of the Japanese Urological Association (Int J Urol) Vol. 13 Issue 6 Pg. 834-7 (Jun 2006) ISSN: 0919-8172 [Print] Australia
• PMID: 16834676 (Publication Type: Case Reports, Clinical Trial, Phase I, Clinical Trial, Phase II, Journal Article)

Chemical References

• Antiviral Agents
• Osteocalcin
• Thymidine Kinase
• Valine
• Valacyclovir
• Acyclovir

Topics

• Acyclovir (administration & dosage, adverse effects, analogs & derivatives)
• Adenoviridae
• Aged
• Antiviral Agents (administration & dosage, adverse effects)
• Bone Neoplasms (secondary, therapy)
• Genetic Therapy (adverse effects, methods)
• Hospitals, University
• Humans
• Japan
• Male
• Middle Aged
• Osteocalcin (genetics)
• Prostatic Neoplasms (genetics, therapy)
• Thymidine Kinase (genetics)
• Valacyclovir
• Valine (administration & dosage, adverse effects, analogs & derivatives)